Your browser doesn't support javascript.
The key role of Calpain in COVID-19 as a therapeutic strategy.
Juibari, Aref Doozandeh; Rezadoost, Mohammad Hossein; Soleimani, Masoud.
  • Juibari AD; Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Rezadoost MH; Biotechnology Department, University of Guilan, Rasht, Iran. rezadoostmh@guilan.ac.ir.
  • Soleimani M; Department of Hematology, Faculty of Medical Sciences, Tarbiat Modarres University, Tehran, Iran.
Inflammopharmacology ; 30(5): 1479-1491, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-2231556
ABSTRACT
COVID-19 is one of the viral diseases that has caused many deaths and financial losses to humans. Using the available information, this virus appears to activate the host cell-death mechanism through Calpain activation. Calpain inhibition can stop its downstream cascade reactions that cause cell death. Given the main roles of Calpain in the entry and pathogenicity of the SARS-CoV-2, its inhibition can be effective in controlling the COVID-19. This review describes how the virus activates Calpain by altering calcium flow. When Calpain was activated, the virus can enter the target cell. Subsequently, many complications of the disease, such as inflammation, cytokine storm and pulmonary fibrosis, are caused by virus-activated Calpain function. Calpain inhibitors appear to be a potential drug to control the disease and prevent death from COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Limits: Humans Language: English Journal: Inflammopharmacology Journal subject: Pharmacology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: S10787-022-01002-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Limits: Humans Language: English Journal: Inflammopharmacology Journal subject: Pharmacology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: S10787-022-01002-1